Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8833035rdf:typepubmed:Citationlld:pubmed
pubmed-article:8833035lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0063710lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0750484lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0017982lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C1517880lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C1705241lld:lifeskim
pubmed-article:8833035lifeskim:mentionsumls-concept:C1705242lld:lifeskim
pubmed-article:8833035pubmed:issue3lld:pubmed
pubmed-article:8833035pubmed:dateCreated1997-5-28lld:pubmed
pubmed-article:8833035pubmed:abstractTextThe extracellular domain of the type I Interleukin-1 receptor (sIL-1R) was expressed in Drosophila S2 cells as a secreted 43 kDa glycoprotein, as evidenced by its binding to Concanavalin A and enzymatic deglycosylation. sIL-1R bound IL-1 beta with a K(D) of 2 nM as determined by competition ELISA. N-Glycanase treated sIL-1R had a C. 100 fold lower affinity than glycosylated sIL-1R for IL-1 beta, suggesting that glycosylation is a key component of the IL-1 beta/IL-1 receptor interaction. Crosslinking of sIL-1R to (125)I-IL-1 beta could be competed with unlabelled IL-1 alpha, IL-1 beta, IL-1 receptor antagonist (IL-1ra), and a mutant of IL-1 (Th9Gly) which has reduced bioactivity but wild type receptor binding affinity. Limited proteolysis of sIL-1R in the presence of IL-1 alpha, IL-1 beta, IL-1ra, and Thr9Gly IL-1 beta with several different proteases followed by analysis of sIL-1R by Western blot was used to assess the effect of binding on sIL-1R conformation. While some proteases showed no differences in cleavage patterns or sensitivity between free and bound sIL-1R, others showed differences in either cleavage sites or sensitivity with different ligands. This implies that upon ligand binding there is a conformational change in the receptor which is sensitive to the particular ligand bound, and hence has implications for the ability of different ligands to trigger responses after binding to receptor.lld:pubmed
pubmed-article:8833035pubmed:languageenglld:pubmed
pubmed-article:8833035pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:citationSubsetIMlld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833035pubmed:statusMEDLINElld:pubmed
pubmed-article:8833035pubmed:monthMarlld:pubmed
pubmed-article:8833035pubmed:issn1043-4666lld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:PorterTTlld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:JacksonJ RJRlld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:EinsteinRRlld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:YoungP RPRlld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:SatheGGlld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:LillquistJ...lld:pubmed
pubmed-article:8833035pubmed:authorpubmed-author:D'AlessioKKlld:pubmed
pubmed-article:8833035pubmed:issnTypePrintlld:pubmed
pubmed-article:8833035pubmed:volume8lld:pubmed
pubmed-article:8833035pubmed:ownerNLMlld:pubmed
pubmed-article:8833035pubmed:authorsCompleteYlld:pubmed
pubmed-article:8833035pubmed:pagination206-13lld:pubmed
pubmed-article:8833035pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:meshHeadingpubmed-meshheading:8833035-...lld:pubmed
pubmed-article:8833035pubmed:year1996lld:pubmed
pubmed-article:8833035pubmed:articleTitleType I IL-1 receptor: ligand specific confirmation differences and the role of glycosylation in ligand binding.lld:pubmed
pubmed-article:8833035pubmed:affiliationDepartment of Molecular Immunology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA.lld:pubmed
pubmed-article:8833035pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8833035lld:pubmed